Solid Tumor Testing Market in the US 2016-2020

Solid Tumor Testing Market in the US 2016-2020

Category : Diagnostic and Biotech
Published On : February  2016
Pages : 50



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
About Solid Tumor Testing Market in the US

Solid tumor testing or screening is done for the early detection of cancer, enabling effective treatment measures to avoid the spread of cancerous cells throughout the body. The testing procedure involves testing of samples such as urine, blood, and other bodily substances. Further, cancer testing also involves conducting genetic tests to analyze certain gene mutations that are linked to certain cancer types. Biopsy, colonoscopy, Papanicolaou (Pap) test, and fecal occult blood tests are some of the tests that are performed for cancer screening.

Technavios analysts forecast the solid tumor testing market in the US to grow at a CAGR of 11.1% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of solid tumor testing products, such as assays or kits and bench-top instruments.

The market is divided into the following segments based on cancer types: 
Breast cancer 
Lung cancer
Colorectal cancer 
Prostate cancer
Cervical cancer 
Other (including pancreatic cysts and thyroid nodules) 

Technavios report, Solid Tumor Testing Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
Abbott Molecular 
Agilent Technologies (Dako)
Beckman Coulter
Roche Diagnostics 

Other prominent vendors 
20/20 GeneSystems
Adaptive Biotechnologies
Advanced Cell Diagnostics
Affymetrix
Agena Bioscience 
Ambry Genetics
ApoCell
Avant Diagnostics
Biological Dynamics
Boditech Med
Becton, Dickinson and Company (BD) 
Biocare Medical
Bio-Rad Laboratories
Castle Biosciences
CDx Diagnostics
Celerus Diagnostics
Cancer Genetics
Caris Life Sciences
Clarient Diagnostic Services
DiaTech Oncology
Enzo Biochem
Epic Sciences
EDP Biotech
Eutropics Pharmaceuticals
Fujirebio Diagnostics
Genalyte
Hologic
Janssen Diagnostics
Myriad Genetics
Omnyx
OxfordGene Technology
Oncospire Genomics
OncoCyte
OvaGene Oncology
Pathway Genomics
Quest Diagnostics
QIAGEN
RiboMed Biotechnologies
Sequenom
Siemens Healthcare Diagnostics
Thermo Fisher Scientific
Tosoh Bioscience
TrimGen

Market driver 
High demand for personalized medicines
For a full, detailed list, view our report 

Market challenge 
Regulatory issues
For a full, detailed list, view our report 

Market trend 
Ready-to-use reagents
For a full, detailed list, view our report 

Key questions answered in this report 
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview
Top-vendor offerings

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Healthcare reform in US
Impact of US healthcare reform on cancer testing industry

PART 06: Reimbursement and coverage: An overview
Current scenario: Validating diagnostic tests
Reimbursement structure in US
Prevailing issues of reimbursement policies

PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis

PART 08: Market segmentation by technology
Conventional testing
Genetic testing

PART 09: Market segmentation by cancer type
Breast cancer
Lung cancer
Colorectal cancer
Prostate cancer
Cervical cancer
Other

PART 10: Market drivers
High demand for personalized medicines
Changes in healthcare system
Rise in demand for POC testing
Increase in molecular testing

PART 11: Impact of drivers

PART 12: Market challenges
Shortage of accurate cancer testing kits
Regulatory issues
Lack of skilled technicians

PART 13: Impact of drivers and challenges

PART 14: Market trends
Use of bench-top mass spectrometer
Ready-to-use reagents

PART 15: Vendor landscape
Competitive scenario
Key vendor analysis 2015
Other prominent vendors

PART 16: Appendix
List of abbreviations

PART 17: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: US healthcare infrastructure before and after healthcare reform
Exhibit 03: Positive and negative impact of US healthcare reform on market
Exhibit 04: Reimbursement perspectives of healthcare entities
Exhibit 05: Solid tumor testing market in US
Exhibit 06: Solid tumor testing market in US 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Segmentation of solid tumor testing market in US by technology 2015
Exhibit 09: Segmentation of solid tumor testing market in US by technology 2020
Exhibit 10: Segmentation of solid tumor testing market in US by technology 2015-2020
Exhibit 11: Solid tumor conventional testing market in US 2015-2020 ($ billions)
Exhibit 12: Solid tumor genetic testing market in US 2015-2020 ($ billions)
Exhibit 13: Segmentation of solid tumor testing market in US by cancer type
Exhibit 14: Segmentation of solid tumor testing market in US by cancer type 2015
Exhibit 15: Segmentation of solid tumor testing market in US by cancer type 2020
Exhibit 16: Segmentation of solid tumor testing market in US by cancer type 2015-2020
Exhibit 17: Solid tumor testing market in US for breast cancer 2015-2020 ($ billions)
Exhibit 18: Solid tumor testing market in US for lung cancer 2015-2020 ($ billions)
Exhibit 19: Solid tumor testing market in US for colorectal cancer 2015-2020 ($ billions)
Exhibit 20: Solid tumor testing market in US for prostate cancer 2015-2020 ($ millions)
Exhibit 21: Solid tumor testing market in US for cervical cancer 2015-2020 ($ millions)
Exhibit 22: Solid tumor testing market in US for other cancers 2015-2020 ($ millions)
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: Abbott Molecular: Key takeaways
Exhibit 26: Agilent Technologies (Dako): Key takeaways
Exhibit 27: Beckman Coulter: Key takeaways
Exhibit 28: Roche Diagnostics: Key takeaways

Enquiry Before Buy